1stOncology™: Cancer Intelligence Service – Page 8193 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline

On June 29, 2021 Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported the signing of a non-exclusive, target-specific license agreement with Innovent Biologics Inc., a leading biopharmaceutical company developing innovative medicines for the treatment of major diseases (Press release, Synaffix, JUN 29, 2021, View Source [SID1234584482]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Under the terms of the agreement, Synaffix will provide all the necessary proprietary ADC technologies including GlycoConnect, HydraSpace and one of its toxSYN linker-payloads, to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate. The deal is the culmination of a successful initial proof-of-concept research period between the companies.

Upon signature, Innovent is granted the rights to deploy the above ADC technologies for one therapeutic molecule. Innovent will be responsible for the research, development, manufacturing and commercialization of the ADC product. Synaffix will closely support Innovent’s research activities and will be responsible for manufacturing components that are specifically related to its proprietary technologies.

Synaffix is eligible to receive an upfront payment, milestone payments related to certain development and sales performance achievements, as well as royalties on potential future commercial sales of the ADC product.

Dr. Yongjun Liu, President of Innovent said:

"We are excited to collaborate with Synaffix as Innovent is expanding its pipeline into the ADC space. Our collaboration with Synaffix adds a promising new ADC candidate to our preclinical pipeline through leveraging Synaffix’s validated, differentiated and innovative ADC technology platform and Innovent’s strong antibody capabilities. Based on Synaffix’s seamless partnering model, we could rapidly combine Synaffix’s ADC technologies with Innovent’s antibody, generate compelling research data and keep moving the project ahead swiftly."

Peter van de Sande, CEO of Synaffix said:

"This is the fourth commercial licensing deal that illustrates the potential of the Synaffix platform to increase the competitive position of our partners within the ADC space. Innovent is an ideal partner for Synaffix due to its strategic focus on innovative medicines and strong R&D capability for high quality biologic drugs. We look forward to working closely together on this exciting development program."

"Central to enhancing our value proposition has been the addition of multiple new proprietary linker-payloads to our ADC technology portfolio. In addition to our well-understood, clinical-stage technologies, GlycoConnect and HydraSpace, our proprietary toxSYN linker-payload platform facilitates any company with an antibody to develop its own highly-competitive ADC."

About The Synaffix ADC Platform Technology
Synaffix’s proprietary ADC technology platform consists of GlycoConnect, HydraSpace and toxSYN linker-payload technologies. Both GlycoConnect and HydraSpace are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability.

GlycoConnect is a conjugation technology that exploits the native antibody glycan for site-specific and stable payload attachment and is tunable to DAR1, DAR2 or DAR4 formats.

HydraSpace is a compact and highly polar spacer technology that is designed to further enhance therapeutic index, particularly with hydrophobic payloads.

toxSYN is a platform of multiple unique linker-payloads that span key, validated mechanisms-of-action for ADC product development.

The combination of these three technologies provides developers with a "one stop" and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary ADC and any ADC developer to expand its pipeline further and increase its competitive position.

In September 2020, Synaffix was recognized with first place in the "Best ADC Platform Technology" award category at the World ADC Awards ceremony following a global review of technologies, voting by industry peers and final evaluation by a panel of independent industry experts.

Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

On June 29, 2021 Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) reported that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC") (Press release, Takeda, JUN 29, 2021, View Source [SID1234584481]). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: View Source

In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at [email protected].

Additionally, Takeda also published today its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. It can be accessed on Takeda’s website at: View Source

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

On June 29, 2021 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, reported that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET (7:30pm BST) (Press release, 4d Pharma, JUN 29, 2021, View Source [SID1234584480]).

A webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com. An archived replay of the webcast will be available for 90 days following the presentation.

Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference

On June 29, 2021 Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, reported that CEO David Giljohann will present a company update as well as participate in a series of 1×1 meetings at the Ladenburg Thalmann 2021 Healthcare Conference occurring July 13-14, 2021 (Press release, Exicure, JUN 29, 2021, View Source [SID1234584479]).

Presentation Date: July 13, 2021
Presentation Time: 1:00-1:25 PM in Track One
Location: The panel discussion will be webcast (available here)

Replays of the presentation will be available on Exicure’s website for 30 days following the presentation.

Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

On June 29, 2021 Boston Children’s Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, reported that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.

The agreement enables Boston Children’s and ElevateBio to form multiple cell and gene therapy companies together; provides Boston Children’s researchers access to ElevateBio’s core-enabling technologies, manufacturing, and leading expertise to advance their programs; and will guarantee Boston Children’s researchers dedicated viral-vector manufacturing space at ElevateBio BaseCamp, ElevateBio’s centralized world-class research and development manufacturing center. In addition, under this agreement, ElevateBio will commit to sponsored research agreements with Boston Children’s investigators as part of the company formation process.

"At Boston Children’s Hospital, we are proud of the foundation we’ve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio – a company so well-positioned to change the face of cell and gene therapy forever – is a natural fit into our overall vision," said David Williams, M.D., formerly Senior Vice President for Research and Chief Scientific Officer, currently Chief of Hematology / Oncology, Boston Children’s Hospital. "Using ElevateBio’s world-class enabling technologies, this alliance will help catalyze the science being conducted in the labs across Boston Children’s, moving potential treatments into the clinic and accelerating the development of multiple cell and gene therapy platforms."

"Boston Children’s Hospital is committed to accelerating the translation of our research into treatments that will improve patients’ lives," said Irene Abrams, Vice President of Technology Development and New Ventures, Boston Children’s Hospital. "and this relationship with ElevateBio is a key part of that effort."

"At ElevateBio, we have built unique end-to-end capabilities that leverage our suite of enabling technologies, technologic know-how, and world-class expertise to advance our own innovative cell and gene therapies as well as accelerate those of industry and academic collaborators," said David Hallal, Chairman and Chief Executive Officer of ElevateBio. "Boston Children’s Hospital has a strong history of innovation in the cell and gene therapy sector through ground-breaking science and spinning out companies to deliver medicines to patients. Through this collaboration, we’re excited to work with the team at Boston Children’s to form new companies, the first of which we’ve identified and will announce later this year, and also enable access to our cutting-edge viral vector manufacturing facilities that will help Boston Children’s researchers move their therapies through development more efficiently."